Close

Anti-CDK5 DNA-encoded mAb (DMAb), pVAX1 (DMAb-0412-CQ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-CDK5 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • CDK5
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 1020
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-0412-CQ CBXC-2427 Mouse IgG1, κ
DMAb-0413-CQ CBXC-0324 Mouse IgG2a
DMAb-0414-CQ CBXC-0325 Mouse IgG1, κ
DMAb-0415-CQ CBXC-0326 Mouse IgG
DMAb-0416-CQ CBXC-2142 Mouse IgG1 Protein expressed in 293T cell transfected with human CDK5 expression vector
DMAb-0417-CQ CBXC-2027 Mouse IgG1 Purified rat Cdk5
DMAb-2826-FY CBFYC-1603 Mouse Human IgM, k
DMAb-2827-FY CBFYC-1604 Mouse Human Recombinant CDK5 (Asp92~Gln273) expressed in E. coli
DMAb-2828-FY CBFYC-1605 Mouse Human IgG1 Purified recombinant human CDK5 (N-terminal) protein fragments expressed in E. coli
DMAb-2829-FY CBFYC-1606 Mouse Human IgG Purified Rat Cdk5
DMAb-2830-FY CBFYC-1607 Mouse Human IgG1 Recombinant protein from human
DMAb-2831-FY CBFYC-1608 Mouse Human IgG1, k His-tagged, recombinant human CDK5 protein purified from E.coli
DMAb-2832-FY CBFYC-1609 Mouse Human IgG2b, k His-tagged, recombinant human CDK5 protein purified from Baculovirus expressed in insect cells
DMAb-2833-FY CBFYC-1610 Mouse Human IgG1, k This CDK5 antibody is generated from a mouse immunized with a recombinant protein of human CDK5
DMAb-2834-FY CBFYC-1611 Mouse Human IgG1 Recombinant cdk5 protein
DMAb-0141-CN EP715Y Rabbit Human IgG Synthetic peptide corresponding to residues in the C-terminus of human Cdk5

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CDK5 DNA-encoded mAb (DMAb), pVAX1 (DMAb-0412-CQ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.